On November 1, 2025, Scott Hutton, president and CEO of Biodesix Inc. (Nasdaq: BDSX), marked a significant milestone by ringing the closing bell at Nasdaq. This event coincided with the five-year anniversary of the company’s initial public offering (IPO) and the successful regaining of compliance with Nasdaq’s listing standards.
Based in Louisville, Biodesix specializes in developing diagnostic tests for lung diseases. Earlier this year, the company faced potential delisting from Nasdaq after its stock price fell below the required $1 minimum for a consecutive 30-day period. A strategic one-for-20 reverse stock split implemented in September allowed Biodesix to regain compliance and stabilize its presence on the exchange.
Reflections on the Journey
As he stood at the Nasdaq exchange, Hutton reflected on the journey over the past five years. “It’s really remarkable to be here today to celebrate the anniversary of our IPO exactly five years ago,” he stated. “The last five years have been exceptionally rewarding and fulfilling for the Biodesix team, who remain committed to partnering with physicians to help those patients in dire need as they battle lung cancer.”
Hutton emphasized the ongoing challenges posed by lung cancer, which remains the deadliest cancer worldwide. He noted that more people are expected to die from lung cancer this year than from the next three most common cancers combined. “At Biodesix, we’re going to remain committed to helping physicians change that,” he affirmed.
Company Overview and Future Plans
Biodesix currently employs around 300 people, with approximately half of its workforce based at its headquarters located at 919 W. Dillon Road, a facility that previously served as a Kohl’s store. The company is scheduled to release its third-quarter financial results on November 3, 2025.
As of November 1, the stock price for Biodesix closed at $6.44, reflecting a decline of 11 cents from the previous day. The leadership of Biodesix continues to focus on innovation and partnership in the field of lung disease diagnostics, aspiring to make a meaningful impact on patient outcomes.
This article was first published by BizWest, an independent news organization, and is republished under a license agreement.
